Cognitive peptide research centers on three primary neurotrophic pathways: BDNF (Brain-Derived Neurotrophic Factor — the primary regulator of synaptic plasticity, long-term potentiation, and adult neurogenesis in the hippocampus; reduced BDNF is associated with depression, cognitive decline, and neurodegenerative disease in preclinical models), NGF (Nerve Growth Factor — the original neurotrophin, critical for cholinergic neuron survival and memory consolidation), and HGF (Hepatocyte Growth Factor — a pleiotropic growth factor with unexpectedly potent cognitive effects mediated through c-Met receptor signaling in hippocampal and cortical neurons).

Peptides that upregulate or mimic these neurotrophins represent a mechanistically rational approach to cognitive enhancement research. The key research question is whether any small peptide can activate the same downstream signaling cascades as full-length neurotrophins — and published data suggests the answer varies considerably by compound and pathway.

A secondary mechanism category involves anxiolytic/stress-axis modulation: cognitive performance in rodent models is heavily influenced by anxiety state, and peptides that reduce stress-axis hyperactivation without sedation (Selank, for example) can produce apparent cognitive improvements partly through anxiety reduction, partly through direct neurological effects.

Semax (ACTH(4-7)PGP) is a synthetic heptapeptide derived from the ACTH 4-10 fragment, developed by the Institute of Molecular Genetics in Russia and registered as a pharmaceutical in Russia and Ukraine for ischemic stroke and optic nerve damage.

Published Semax research documents consistent BDNF upregulation in rodent hippocampus and cortex following intranasal administration. A 2001 study in *Cellular and Molecular Neurobiology* demonstrated that intranasal Semax significantly increased BDNF and NGF mRNA expression in rat brain tissue within hours of administration. Subsequent research confirmed VEGF upregulation alongside BDNF, suggesting vascular as well as neurological activity.

Cognitive endpoints in published Semax studies include improved spatial memory in Morris Water Maze tasks, faster learning in active avoidance paradigms, and accelerated recovery of cognitive function in ischemia models. The compound is notable for its intranasal bioavailability — it crosses the blood-brain barrier via olfactory epithelium transport, making it the most CNS-accessible peptide in this comparison without requiring invasive administration.

Semax also has documented clinical use in Russia, providing a translational bridge that most peptides in this class lack. Published Russian clinical data in stroke and optic atrophy populations, while not meeting modern Western RCT standards, provide a human data reference point.

Selank (TKPRPGP) is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg), also developed by the Institute of Molecular Genetics in Russia. It is registered in Russia as an anxiolytic.

Selank's primary research mechanism is GABAergic modulation combined with IL-6 pathway normalization. Published Russian research has shown Selank increases expression of GABA-A receptor subunits and potentiates GABAergic inhibition without causing benzodiazepine-like sedation or receptor downregulation. A 2014 publication in *Zhurnal Vysshei Nervnoi Deiatelnosti* reported that Selank normalized IL-6 expression in rat models of anxiety and produced stable anxiolytic effects over repeated administration.

For cognitive research specifically, Selank's profile is somewhat distinct from the others: its cognitive effects appear largely secondary to anxiety reduction. In high-anxiety animal models and preliminary human studies, Selank reduces stress-impaired cognition, improving performance on attention and memory tasks that deteriorate under stress. This mechanism is highly relevant to research into stress-induced cognitive impairment, but less relevant to studying direct neuroplasticity enhancement.

Selank is also studied for its immunomodulatory properties through Tuftsin-like activity — modulating natural killer cell activity and phagocyte function. These dual cognitive/immune research applications make it a unique compound in the peptide nootropic category.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small hexapeptide developed at Washington State University by Joseph Harding's laboratory. Its mechanism is among the most characterized in cognitive peptide research: Dihexa is a potent HGF/c-Met agonist that activates hepatocyte growth factor signaling in hippocampal neurons.

Published research from the Harding lab (McCoy et al., 2013 in *Neuropsychopharmacology*) demonstrated that Dihexa was orders of magnitude more potent than BDNF itself at inducing hippocampal synaptogenesis in vitro — a landmark finding that positioned it as potentially the most potent pro-cognitive peptide described to that date. The HGF/c-Met pathway drives dendritic arborization, synapse formation, and spatial learning in animal models.

In published in vivo studies, Dihexa administered by subcutaneous injection or transdermal application in rodents produced measurable improvements in Morris Water Maze performance and object recognition tasks in cognitively impaired animals. The compound is particularly studied for neurodegeneration-associated cognitive decline — the HGF/c-Met pathway is activated endogenously in response to neuronal injury, and Dihexa may amplify this recovery signal.

Dihexa is notable for its oral bioavailability and blood-brain barrier penetration — properties unusual for a peptide — which are attributed to its small size and lipophilic modifications. These properties make it accessible for varied administration route studies.

Cerebrolysin is a peptide mixture derived from porcine brain proteins through enzymatic hydrolysis, developed in Austria and marketed in over 50 countries for neurological indications. It contains a complex mixture of low-molecular-weight neuropeptides and amino acids, including fragments with BDNF-like, NGF-like, and CNTF-like bioactivity.

Unlike the single-compound peptides in this comparison, Cerebrolysin is a polypeptide mixture — its complexity is both a strength (multi-pathway activation) and a challenge for mechanism attribution. Published research has demonstrated BDNF-like and NGF-like activity in neuronal culture models, with Cerebrolysin promoting neurite outgrowth, increasing synaptic density, and reducing glutamate-induced excitotoxicity.

Cerebrolysin has the largest human clinical dataset of any compound in this category. Multiple randomized controlled trials have studied it in Alzheimer's disease, vascular dementia, and post-stroke rehabilitation. A 2020 Cochrane review found evidence supporting cognitive benefit in dementia populations, though noting limitations in trial quality. For researchers, this clinical evidence base provides a meaningful translational anchor that single-compound peptides currently lack.

In combination research contexts, Cerebrolysin is sometimes studied alongside more targeted compounds — its broad neurotrophic spectrum may complement the more specific HGF pathway (Dihexa) or GABAergic (Selank) mechanisms.

For researchers designing cognitive peptide protocols, the four compounds occupy distinct niches:

Semax — Best for BDNF/NGF upregulation and intranasal CNS delivery research. Most useful for neuroplasticity, ischemia recovery, and optic nerve research. The most clinically validated (Russian registration).

Selank — Best for anxiety-cognition interaction research. Most useful for stress-impaired cognition models and GABAergic modulation studies. Combined cognitive-immunological research applications.

Dihexa — Best for synaptogenesis and HGF/c-Met pathway research. Most useful for neurodegeneration models and studying mechanisms of synaptic repair. Notable for its extraordinary potency in published in vitro synaptogenesis assays.

Cerebrolysin — Best for translational research with the largest human evidence base. Most useful for Alzheimer's, vascular dementia, and post-stroke research where human clinical data is required. Its polypeptide composition provides multi-pathway activation relevant to complex cognitive phenotypes.

All compounds are classified as research-use-only substances. They are not approved by the FDA or EMA for cognitive enhancement and are studied exclusively in preclinical and controlled research contexts.